Mankind Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Results View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹2470.00

prior close

₹2501.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+4.1% vs market

Pharmaceuticals peers, median of 158sector+0.2%+4.2% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+2.1

15m

+2.2

30m

+2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+0.4+4.1+0.2+4.2

Next day

+2.0+0.5+1.5+0.7+1.3

+0.4+0.6-0.1+0.5-0.1

-0.4+1.4-1.9+1.8-2.2

-2.2+1.9-4.1+1.9-4.2

-1.5+2.3-3.7+2.0-3.5

-6.2-0.5-5.7+1.3-7.5

15d

-3.8-2.9-1.0-0.5-3.3

+3.0+3.1-0.2+4.1-1.1

+4.3+3.2+1.1+8.4-4.1

-3.4+4.5-8.0+9.1-12.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma Limited has submitted its financial results for Q4 and FY2026 (ending March 31, 2026) to the stock exchange. This is a standard periodic disclosure filing as required under SEBI listing regulations. The announcement headline does not provide specific financial figures, details about revenue, profit margins, or any notable items that would warrant investor attention. Detailed results would need to be reviewed separately to assess actual performance.

Likely market impact

The filing represents routine disclosure of financial performance. Without specific numbers in the headline, the market will need to review the detailed results to assess company performance. No immediate stock-specific impact can be determined from this announcement alone.